Navigation Links
Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol
Date:4/26/2010

ompound miravirsen, the International Nonproprietary Name (INN) or generic name for the compound formerly known as SPC3649.

Miravirsen, the first microRNA-targeted drug to enter human clinical trials, is a specific inhibitor of miR-122, a liver-specific microRNA that the Hepatitis C virus requires for replication. Unlike Hepatitis C therapies that directly target the virus, miravirsen works by removing a "helper" molecule (miR-122) that the virus needs in order to make new copies. Miravirsen is being studied in a Phase 1 trial multiple-ascending dose study in healthy volunteers and a Phase 2 study in patients infected with Hepatitis C is expected to begin in the second half of 2010.

Santaris Pharma A/S also has a broad range of drug discovery and development programs with its partners: Shire plc (lead candidates against up to five targets for rare genetic disorders), Pfizer (lead candidates against up to ten targets), GlaxoSmithKline (options to drug candidates from up to four viral disease programs) and Enzon Pharmaceuticals (lead candidates against eight cancer targets successfully delivered).

About Locked Nucleic Acid (LNA) Drug Platform

The LNA Drug Platform utilizing Santaris Pharma A/S proprietary LNA chemistry provides the key to delivering on the promise of RNA-targeted therapies today by addressing these concerns and overcoming the limitations of earlier antisense and siRNA technologies to deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The unique combination of small size and very high affinity, which is only achievable with LNA-based drugs, allows this new class of drugs to potently and specifically inhibit RNA-targets in many different tissues without the need for complex delivery vehicles. LNA-based drugs are a promising new type of therapy that enables scientists to develo
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
5. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
6. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
7. New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations
8. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
9. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... DUBLIN , May 27, 2015 ... addition of Jain PharmaBiotech,s new report "Cell ... their offering. This report describes and ... already started to play an important role in ... is replacing the old fashioned bone marrow transplants. ...
(Date:5/28/2015)... CARLOS, Calif. , May 28, 2015 /PRNewswire/ ... testing, today announced a study published in ... the Panorama single-nucleotide polymorphism (SNP)-based non-invasive prenatal test ... the first trimester. A study ... that complete molar pregnancies occur in about 1 ...
(Date:5/28/2015)... MARLBOROUGH, Mass. , May 28, 2015 ... company focused on discovering and developing innovative therapeutics, primarily ... the pricing of a public offering of 26 million ... per share for gross proceeds of approximately $10.4 million. ... stock, (ii) a 13-month overallotment purchase right to purchase ...
(Date:5/28/2015)... 28, 2015 The Fertility Centers of ... Dr. Danielle Vitiello has taken on a new and ... Vitiello will provide guidance, leadership, oversight and quality assurance ... Dr. Vitiello among our team of experienced reproductive endocrinologists,” ... Joseph A. Hill, M.D. “Her expertise and compassionate, individualized ...
Breaking Biology Technology:Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2
... October 20, 2011 -- "Working Toward a ... Key Trends in Breast Cancer Research Article Output -- ... scientific community in the publication of breast cancer research articles, ... a Cure: Examining   the State of Global Breast Cancer ...
... DIEGO, Oct. 20, 2011 Verenium Corporation (Nasdaq: ... and commercializing high-performance enzymes, today announced that it has ... Export-Import Bank of the United States ("Ex-Im Bank") for ... $13 million. These new credit facilities ...
... PARIS, October 20, 2011 - New findings from the ... ACTRIMS Congress - - U.S. FDA Accepts New ... - Sanofi (EURONEXT: SAN and NYSE: ... pivotal TE riflunomide M ultiple S clerosis O ...
Cached Biology Technology:United States Holds Global Lead in Breast Cancer Research Publications as China Surges to Forefront, According to Report 2United States Holds Global Lead in Breast Cancer Research Publications as China Surges to Forefront, According to Report 3United States Holds Global Lead in Breast Cancer Research Publications as China Surges to Forefront, According to Report 4United States Holds Global Lead in Breast Cancer Research Publications as China Surges to Forefront, According to Report 5Verenium Announces Up to $16 Million in New Secured Financings 2Verenium Announces Up to $16 Million in New Secured Financings 3Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis 2Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis 3Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis 4Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis 5Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis 6
(Date:5/6/2015)... TEL AVIV, Israel , May 6, 2015 /PRNewswire/ ... the world,s most established helmet producer, announced today that ... LifeBEAM Smart Helmet, the world,s first bio-sensing cycling helmet ... will be released in two new colors in order ... demand for the product. In addition, LifeBEAM and Lazer ...
(Date:4/27/2015)... , Apr. 27, 2015 Profile Solutions, Inc. ... and security systems is pleased to announce that Dr ... a consultant and member of its scientific advisory board. ... known as a thought leader in technology-enhanced learning models. ... Group, and has published studies and books focused on ...
(Date:4/17/2015)... April 17, 2015 ... and technological advancement to drive biometric systems market ... 2020   According to a recently ... Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... register growth at CAGR of over 22% through ...
Breaking Biology News(10 mins):LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... NY The Feinstein Institute for Medical Research today ... Massachusetts Institute of Technology (MIT) being spearheaded by GlaxoSmithKline ... impulses to regulate the body,s organs and functions. This ... Nature . "This is a powerful collaboration between ...
... of cases, novel drugs tested on humans by pharmaceutical companies do ... drugs do not work, while at worst, test subjects die.,New research ... can be reduced. The secret is to test the drug on ... of 15 liver patients who participated in a medical trial following ...
... at the University of York and the Royal Society for ... have colonised the UK in recent decades breed initially almost ... wildlife., First author, Jonathan Hiley, a PhD student in the ... welcome mats for new arrivals.", Published online in the journal ...
Cached Biology News:Feinstein Institute collaborates with GSK, UPenn, MIT to research body's electrical impulses 2New cutting-edge cell research will lead to safer medical experiments on humans 2New cutting-edge cell research will lead to safer medical experiments on humans 3New cutting-edge cell research will lead to safer medical experiments on humans 4Protected wildlife areas are 'welcome mats' for UK's bird newcomers 2
Proliferin (C-14)...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
... Ascent is a dedicated fluorometer ... all kinds of assays in ... for clinical applications. Cell biology, ... all important application areas. Robot-friendly ...
... SpeedVac Concentrator, the SPD series takes the ... modern twist., The SPD121P SpeedVac comes equipped ... optimizing runs; preventing samples from freezing; and ... the end-users preset level., Standard features on ...
Biology Products: